GB9924962D0 - Allosteric sites on muscarinic receptors - Google Patents

Allosteric sites on muscarinic receptors

Info

Publication number
GB9924962D0
GB9924962D0 GBGB9924962.5A GB9924962A GB9924962D0 GB 9924962 D0 GB9924962 D0 GB 9924962D0 GB 9924962 A GB9924962 A GB 9924962A GB 9924962 D0 GB9924962 D0 GB 9924962D0
Authority
GB
United Kingdom
Prior art keywords
muscarinic receptors
allosteric sites
allosteric
sites
muscarinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9924962.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MRC COLLABORATIVE CENTRE
Original Assignee
MRC COLLABORATIVE CENTRE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MRC COLLABORATIVE CENTRE filed Critical MRC COLLABORATIVE CENTRE
Priority to GBGB9924962.5A priority Critical patent/GB9924962D0/en
Publication of GB9924962D0 publication Critical patent/GB9924962D0/en
Priority to JP2001531835A priority patent/JP2003512607A/ja
Priority to AU10383/01A priority patent/AU779391B2/en
Priority to PCT/GB2000/004064 priority patent/WO2001029036A2/fr
Priority to CA002386149A priority patent/CA2386149A1/fr
Priority to EP00971543A priority patent/EP1222463A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
GBGB9924962.5A 1999-10-21 1999-10-21 Allosteric sites on muscarinic receptors Ceased GB9924962D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9924962.5A GB9924962D0 (en) 1999-10-21 1999-10-21 Allosteric sites on muscarinic receptors
JP2001531835A JP2003512607A (ja) 1999-10-21 2000-10-20 ムスカリン受容体のアロステリック部位
AU10383/01A AU779391B2 (en) 1999-10-21 2000-10-20 Allosteric sites on muscarinic receptors
PCT/GB2000/004064 WO2001029036A2 (fr) 1999-10-21 2000-10-20 Sites allosteriques sur des recepteurs muscariniques
CA002386149A CA2386149A1 (fr) 1999-10-21 2000-10-20 Sites allosteriques sur des recepteurs muscariniques
EP00971543A EP1222463A2 (fr) 1999-10-21 2000-10-20 Sites allosteriques sur des recepteurs muscariniques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924962.5A GB9924962D0 (en) 1999-10-21 1999-10-21 Allosteric sites on muscarinic receptors

Publications (1)

Publication Number Publication Date
GB9924962D0 true GB9924962D0 (en) 1999-12-22

Family

ID=10863158

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9924962.5A Ceased GB9924962D0 (en) 1999-10-21 1999-10-21 Allosteric sites on muscarinic receptors

Country Status (6)

Country Link
EP (1) EP1222463A2 (fr)
JP (1) JP2003512607A (fr)
AU (1) AU779391B2 (fr)
CA (1) CA2386149A1 (fr)
GB (1) GB9924962D0 (fr)
WO (1) WO2001029036A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084889A1 (fr) * 2003-03-28 2004-10-07 Pfizer Inc. Utilisation de l'inhibiteur de la proteinekinase c pour supprimer l'excitation postsynaptique lente soutenue (sspe) de neurones enteriques
CN100577666C (zh) * 2004-10-25 2010-01-06 伊莱利利公司 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
CN101808994B (zh) 2007-07-17 2013-05-15 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747336A (en) * 1988-09-08 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Cloned human genes for muscarinic acetylcholine receptors and cells lines expressing same
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
CZ24197A3 (en) * 1994-07-27 1997-08-13 Sankyo Co Heterocyclic compounds, usable as allosteric efectors in muscarine receptors
EP0711557A1 (fr) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Base pour formulations pharmaceutiques
US5677327A (en) * 1995-06-22 1997-10-14 Allergan Method for identifying muscarinic agents lacking miotic side effects

Also Published As

Publication number Publication date
AU779391B2 (en) 2005-01-20
CA2386149A1 (fr) 2001-04-26
AU1038301A (en) 2001-04-30
WO2001029036A2 (fr) 2001-04-26
JP2003512607A (ja) 2003-04-02
EP1222463A2 (fr) 2002-07-17
WO2001029036A3 (fr) 2002-05-10

Similar Documents

Publication Publication Date Title
AU6103000A (en) Compounds with activity on muscarinic receptors
PL352377A1 (en) Valve-type metering device for multiple-stream metering
HK1054391A1 (zh) 毒蕈碱拮抗劑
SG80041A1 (en) Muscarinic receptor antagonists
GB2348495B (en) Levelling device
IL140249A0 (en) Muscarinic antagonists
GB2357461B (en) Fixing device
GB0010476D0 (en) Keybutton-equipped device
HUP0002370A3 (en) Hinge device
GB9924962D0 (en) Allosteric sites on muscarinic receptors
IL146151A0 (en) Human-g-protein receptor
HK1043590A1 (zh) 毒蕈碱性拮抗物
AU4511901A (en) Nonpeptide kappa opioid receptor antagonists
GB0006110D0 (en) Wear-warning device
EP1115266A4 (fr) Dispositif de reproduction sonore
GB2356166B (en) Extension device for wheelbraces
GB9921144D0 (en) Levelling device
TW472906U (en) Fixing device
GB9908491D0 (en) Fixing device
GB2356425B (en) Fixing device
TW424568U (en) Improved structure for dust-gathering device
ZA200003475B (en) Muscarinic receptor antagonists.
TW444989U (en) Improved structure for handsfree device
GB2349932B (en) Fixing device
AU2512800A (en) Alpha1-adrenergic receptor antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)